During drug development, ADME characterization is critical to measuring the kinetics of drug exposure and overall performance and toxicity within an organism. It is traditionally used during the later stages of lead optimization. Increasingly, though, research organizations are demanding earlier ADME-Tox studies to reduce late-phase drug failures and the associated costs.
Ensure your drug candidates are well characterized and development costs are minimized
IC50 = 63.87 + 0.04 nM
Significantly Improved Characterization
Characterizationon of Absorption, Distribution, Metabolism, and Excretion (ADME) and Toxicity drug profiles are a critical step in drug development. Due to the expense of drug candidates failing into clinical trials, it is key to accurately determine drug characteristics earlier, and ideally in a cost effective manner. Using the Echo liquid handler, researchers are successfully implementing comprehensive ADME-Tox screens during the early stages of drug discovery, helping to ensure that drug candidates are well characterized and development costs are minimized. The low transfer volume increments of the Echo Liquid Handlers enable total volume miniaturization without sacrificing data quality. Non-contact transfer of drug candidates ensures that interferences from traditional liquid handling techniques (such as hydrophobic interactions with plastic tips) are minimized.
Reduced reaction volumes and increased throughput for a range of ADME-Tox assays
Intuitive software applications to multiplex assays and dose-response conditions
Walk-up automation with the benefits of Echo liquid handling technology
Minimal training requirements
A New Approach to Early ADME CYP450 Inhibition Profiling Using the Echo Liquid Handler
Jing Wang|Applications Scientist, Labcyte Inc.
The high cost of drug discovery and the frequent failure of compounds due to poor ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) properties necessitate an earlier study of ADMET profiles...